Insider Buying: Immunic, Inc. (NASDAQ:IMUX) CEO Purchases 15,000 Shares of Stock

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) CEO Daniel Vitt purchased 15,000 shares of the business's stock in a transaction that occurred on Wednesday, June 4th. The stock was bought at an average cost of $0.77 per share, for a total transaction of $11,550.00. Following the completion of the acquisition, the chief executive officer now directly owns 29,000 shares of the company's stock, valued at $22,330. This represents a 107.14% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Immunic Stock Performance

Shares of NASDAQ IMUX traded up $0.02 during trading on Friday, hitting $0.79. The company had a trading volume of 2,456,208 shares, compared to its average volume of 858,603. The company has a market cap of $75.54 million, a P/E ratio of -0.64 and a beta of 1.73. The business's 50-day moving average is $0.97 and its 200 day moving average is $1.05. Immunic, Inc. has a 52 week low of $0.56 and a 52 week high of $2.11.

Immunic (NASDAQ:IMUX - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.25) EPS for the quarter, meeting the consensus estimate of ($0.25). On average, research analysts expect that Immunic, Inc. will post -0.94 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on IMUX. Wall Street Zen downgraded shares of Immunic from a "hold" rating to a "sell" rating in a research report on Thursday, March 20th. B. Riley restated a "buy" rating and issued a $5.00 target price (down from $6.00) on shares of Immunic in a research note on Friday, May 23rd. D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Immunic in a report on Thursday. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Immunic in a research report on Thursday, May 1st. Finally, William Blair restated an "outperform" rating on shares of Immunic in a research report on Friday, May 16th. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Immunic presently has a consensus rating of "Buy" and an average target price of $11.60.

Institutional Trading of Immunic

A number of hedge funds have recently bought and sold shares of IMUX. Invesco Ltd. purchased a new position in shares of Immunic in the fourth quarter worth approximately $37,000. Barclays PLC acquired a new position in Immunic in the 4th quarter worth approximately $84,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Immunic by 90.0% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company's stock worth $205,000 after purchasing an additional 96,894 shares during the period. Jane Street Group LLC grew its position in Immunic by 279.3% during the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock worth $226,000 after purchasing an additional 152,726 shares in the last quarter. Finally, Bridgeway Capital Management LLC raised its stake in Immunic by 11.5% during the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock valued at $215,000 after purchasing an additional 22,200 shares during the period. 51.82% of the stock is owned by hedge funds and other institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.